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TransplantatABSTRACT
Background. The clinical safety and efﬁcacy of sirolimus plus reduced-dose tacrolimus
was evaluated in de novo renal allograft recipients enrolled in a comparative, open-label
study.
Methods. One hundred twenty-eight renal allograft recipients were randomly assigned
(1:1) to receive reduced-dose tacrolimus plus sirolimus (rTAC) or standard-dose
tacrolimus and sirolimus (sTAC) for 6 months. The primary efﬁcacy endpoint was
calculated creatinine clearance values at 6 months.
Results. Demographic variables were similar between groups. At 6 months, mean
( standard deviation) calculated creatinine clearance was signiﬁcantly improved in the
rTAC group (63.8 vs 52.7 mL/min, P ¼ .005), although mean serum creatinine values were
not signiﬁcantly different. Patient survival (95.2% and 96.9%) and graft survival (93.7%
and 98.5%) were similar between the rTAC and sTAC groups, respectively. Acute rejection
rates were 17.5% with rTAC and 7.7% with sTAC (P ¼ .095).
Conclusions. The rTAC regimen provided effective immunosuppression and was asso-
ciated with improved creatinine clearance. Adequate immunosuppressant exposure must
be achieved in the early postoperative period to minimize the risk of acute rejection.From the Ruhr-Universitat (W.O.B.), Bochum, Germany;
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Germany. E-mail: Wolf.Bechstein@kgu.deSINCE THEIR INTRODUCTION, the calcineurininhibitors (CNIs) cyclosporine and tacrolimus have
generally remained the cornerstones of immunosuppressive
protocols. The use of CNIs, however, may be complicated
by toxicities, including hypertension, post-transplant dia-
betes, hyperlipidemia, and nephrotoxicity. Toxicity with
CNIs is known to contribute to a long-term decline in renal
function and to the development of chronic allograft
nephropathy.1-5 Because of these limitations, signiﬁcant
research efforts are directed toward developing immuno-
suppressive strategies that minimize or eliminate the use of
CNIs. Immunosuppressive protocols using agents such as
sirolimus (rapamycin; Rapamune) may reduce or eliminate
chronic exposure to CNIs, with the potential beneﬁt of
improving renal allograft function and outcomes.
Sirolimus, a macrocyclic lactone isolated from Strepto-
myces hygroscopicus, is a potent immunosuppressive agent
with a multifaceted mechanism of action distinct from that
of CNIs.6 Sirolimus does not inhibit the activity of calci-
neurin phosphatase. It forms a complex with FKBP-12 thatlished by Elsevier Inc.
enue South, New York, NY 10010-1710
ion Proceedings, 45, 2133e2140 (2013)binds to the mammalian target of rapamycin, a speciﬁc cell-
cycle regulatory protein, inhibiting cytokine-induced signal
transduction pathways and arresting the cell cycle in the
G1-S phase.7 Sirolimus also inhibits various growth factors
that are critical in regulating and inhibiting the proliferation
and migration of vascular smooth muscle cells and has been0041-1345/13/$esee front matter
http://dx.doi.org/10.1016/j.transproceed.2013.03.025
2133
2134 BECHSTEIN, PACZEK, WRAMNER ET ALshown to inhibit arterial intimal thickening in animal models
and humans.8-12
Because sirolimus and tacrolimus share a common
immunophilin (FKBP-12), the combination of sirolimus and
tacrolimus was initially believed to be antagonistic.13,14
Early preclinical experience, however, indicated that the
sirolimus-tacrolimus combination exhibited immunosup-
pressive synergy.15 Only a small fraction of the abundant
FKBP-12 immunophilin needs to be occupied by these
agents to achieve maximal immunosuppression.16 There is
an expanding body of literature on the successful clinical
application of the combination of sirolimus- and tacrolimus-
based immunosuppression in renal and nonerenal allograft
recipients.17-25
In an attempt to minimize the toxicity of tacrolimus, this
study was designed to investigate the clinical safety and
efﬁcacy of a regimen of sirolimus plus reduced-dose tacro-
limus (rTAC) in renal allograft recipients.
METHODS
This 6-month, randomized, open-label trial enrolled 128 de novo
renal allograft recipients at 13 European sites. The study was con-
ducted in accordance with guidelines established by the Declaration
of Helsinki and was completed in June 2002. Approval was granted
by the institutional review board or human ethics committee of each
study center. Each enrolled patient provided written informed
consent.
Patient Population
All patients (n ¼ 128) were aged 18 years or older and received
either a primary or secondary renal allograft from a deceased
donor. Patients with secondary transplants must have maintained
their primary graft for a minimum of 6 months to be eligible (with
the exception of patients who had lost their primary graft within
6 months secondary to a technical complication). Women of
childbearing potential were required to have a negative pregnancy
test result before sirolimus administration and to use a medically
acceptable method of contraception. Patients were excluded if they
had a systemic infection, human immunodeﬁciency virus, active
hepatitis B or C, history of malignancy within the previous 5 years
(except for adequately treated basal cell or squamous cell carci-
noma of the skin), known hypersensitivity to sirolimus or tacrolimus
or their derivatives, and a screening or baseline white blood cell
count  3000/mm3 or platelet count  100,000/mm3. Use of an
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BID, twice daily; rTAC, reduced-dose tacrolimus; sTAC, standard-dose tacrolimus
aDosing adjusted to maintain 24-h whole blood trough levels.or during the 6-month treatment phase was prohibited. Patients
planning to use medications known to interact with sirolimus were
excluded. Use of terfenadine, cisapride, astemizole, pimozide, or
ketoconazole must have been discontinued before receiving siroli-
mus. Patients receiving multiple organ transplants, allografts with
cold ischemia times longer than 36 hours, allografts obtained from
donors after cardiac death, or allografts from donors older than
65 years were excluded. Patients at high risk for acute rejection
(AR) were excluded, including those with recent panel-reactive
antibodies >50%.
Immunosuppressive Therapy
Patients were randomly assigned 1:1 before transplantation to
receive corticosteroids and sirolimus oral solution in combination
with either rTAC or standard-dose tacrolimus (sTAC). All patients
received corticosteroids according to a standardized taper regimen:
post-transplant day (PTD) 0, 500 mg methylprednisolone intrave-
nously (IV); PTD 1, 125 mg methylprednisolone IV; PTD 2 to week
2, prednisone 20 mg orally (PO) daily; weeks 2 to 4, prednisone
15 mg PO daily; months 1 to 2, prednisone 10 mg PO daily; months
3 to 6 prednisone 5 mg PO daily. Planned antibody induction within
1 week before or at the time of transplantation was not permitted;
however, the use of antibody therapy was allowed to manage sus-
pected AR, steroid-resistant rejection, or delayed graft function.
Concurrent use of other immunosuppressive therapies, including
Neoral (cyclosporine), CellCept (mycophenolate mofetil), or
azathioprine, was not allowed.
Administration of sirolimus oral solution (1 mg/mL) was initiated
within 48 hours after transplantation. In the rTAC group, patients
received an initial sirolimus loading dose of 15 mg on day 1, then
5 mg daily adjusted to maintain 24-hour whole blood trough levels,
assessed via high-performance liquid chromatography-mass spec-
tometry (Table 1). Tacrolimus was initiated within 7 days after
transplantation at a dose of 0.03 mg/kg twice daily, adjusted to
maintain trough levels of 3 to 7 ng/mL throughout the study period.
In the sTAC group, patients received an initial sirolimus loading
dose of 6 mg on day 1, then 2 mg daily adjusted to maintain 24-hour
whole blood trough levels of 5 to 10 ng/mL throughout the study.
Tacrolimus was initiated within 7 days after transplantation at
a dose of 0.05 mg/kg twice daily, adjusted to maintain target trough
levels (Table 1).
Soon after study enrollment began, an increased incidence of AR
was identiﬁed in the rTAC group. Analysis of this patient group
revealed that target sirolimus and tacrolimus levels were not being
achieved by day 7. The protocol was therefore amended to mandate
an increase in the sirolimus loading dose to 15 mg for 3 days, and
the initial sirolimus daily dose was increased to 5 mg in both groups
(Table 1). In the rTAC group, the initial tacrolimus dose wasntrations of Sirolimus and Tacrolimus
sTAC group
crolimus Sirolimus Tacrolimus
mg/kg BIDa 6 mg (day 1), then 2 mg QDa 0.05 mg/kg BIDa




; QD, once daily.
Table 2. Baseline Patient Characteristicsa
Characteristic rTAC (n ¼ 63) sTAC (n ¼ 65)
Male, n (%) 45 (71.4) 38 (58.5)
White (%) 100 100
Mean age (y  SD) 47.9  13.3 44.6  14.8
Deceased donor source, n (%) 62 (98.4)b 65 (100.0)
Primary transplant, n (%) 54 (85.7) 60 (92.3)
Mean ischemia time (h  SD) 17.6  6.6 17.9  6.9
Mean HLA mismatches  SD 2.9  1.3 2.9  1.4
Mean panel reactive antibody (%  SD) 2.5  7.3 3.2  11.7
Delayed graft function, n (%) 19 (30.2) 20 (30.8)
Cause of end-stage renal disease, n (%)
Glomerulonephritis 17 (27.0) 25 (38.5)
Diabetes mellitus 5 (7.9) 8 (12.3)
Polycystic kidney disease 11 (17.5) 6 (9.2)
Hypertension 3 (4.8) 5 (7.7)
Interstitial disease 5 (7.9) 4 (6.2)
Other/unknown 22 (34.9) 17 (26.2)
rTAC, reduced-dose tacrolimus; sTAC, standard-dose tacrolimus; SD; stan-
dard deviation; HLA; human leukocyte antigen.
aNo statistically signiﬁcant differences between groups.
bDonor source not recorded in 1 patient.
SIROLIMUS PLUS REDUCED-DOSE TAC 2135increased to 0.05 mg/kg. Target sirolimus and tacrolimus concen-
trations were not changed.
Required Concomitant Treatment
Prophylaxis for Pneumocystis carinii pneumonia was required for
all patients throughout the treatment period. Trimethoprim-
sulfamethoxazole was the preferred therapy, although alternative
agents were permitted in accordance with local standards of care.
Cytomegalovirus-negative recipients of an allograft from a cyto-
megalovirus-positive donor received cytomegalovirus prophylaxis
for 3 months after transplantation, according to local practice.
Acute Rejection
Patients with clinically suspected AR underwent a biopsy to
conﬁrm the diagnosis, unless contraindicated. The histologic
diagnosis and severity grade of AR was scored according to the
1997 Banff classiﬁcation26 by a local pathologist who was blinded
to treatment. Biopsy-conﬁrmed AR (BCAR) included only those
episodes in which the Banff AR grade was at least IA. Clinical AR
was deﬁned as all ﬁrst BCARs plus those treated episodes in which
a biopsy was not performed or was graded as borderline. Initial
therapy for AR consisted of pulse corticosteroids, according to
local standards of care. Patients who did not respond to cortico-
steroids could receive antibody therapy and were eligible to
continue in the study at the discretion of the investigator. Patients
who required other maintenance immunosuppressive agents were
withdrawn from the study.
Graft Loss
Graft loss was deﬁned as (1) a deterioration of renal function
sufﬁcient to require a transplant nephrectomy; (2) reinitiation of
dialysis for more than 8 weeks; (3) retransplantation; or (4) death
with a functioning graft.
Endpoints
The primary endpoint was graft function as assessed by calculated
creatinine clearance using the method of Nankivell27 at 6 months
posttransplant. Secondary efﬁcacy endpoints at 6 months included
graft function as assessed by serum creatinine, the incidence of
BCARs and presumptive ARs, the time to ﬁrst BCAR, the severity
of AR (including histologic grade), patient and graft survival, the
incidence of infection (conﬁrmed, presumptive, and opportunistic),
histologically conﬁrmed lymphoproliferative disease or malignancy,
new-onset diabetes mellitus, and premature withdrawal from study
medication.
Safety Assessment
Safety was assessed via routine physical examinations, which
included measurement of weight and vital signs, electrocardio-
grams, complete blood chemistries, blood counts, serum creatinine
levels, calculated creatinine clearance, and fasting lipid proﬁles.
Chest radiographs were performed before enrollment and as clini-
cally indicated. All adverse events were recorded, and study
participants were monitored for infections, malignancies, and lym-
phoproliferative disease.
Statistical Analysis
It was estimated that a sample size of 70 patients per group would
have 90% power to detect a difference in mean serum creatinine as
small as 27.5 mmol/L, assuming a standard deviation (SD) of 50,with a 0.050 2-tailed signiﬁcance level, which was expected to be
highly correlated with the primary endpoint, Nankivell creatinine
clearance. Based on the actual number of enrolled and completed
patients and the observed variability, there was approximately 80%
power to detect this difference. Continuous data were expressed as
means  SD and categorical data were expressed as numbers and
percentages. The primary analysis was a t test examining the
difference in means between the 2 treatment groups. Fisher exact
test was used for comparison of adverse events and other categor-
ical variables, and one-way analysis of variance was used for
continuous variables. Graft loss and patient death were analyzed
using the Kaplan-Meier method for estimation of time to events.
The log-rank test was used to assess statistical differences in the
time-to-event analysis between groups. The distribution of histo-
logic grade of ﬁrst ARs in the 2 treatment groups was compared
using a generalized Cochran-Mantel-Haenszel row mean score test.
Differences in sirolimus and tacrolimus trough levels were analyzed
via t tests at each time point.
RESULTS
Demographics and Baseline Characteristics
Of the 128 enrolled patients, 63 were randomly assigned to
rTAC and 65 were randomly assigned to sTAC. Patient
demographics were similar between the two groups
(Table 2). Recipients ranged in age from 18 to 78 years,
64.8% were male, and all were white. Overall, the most
common primary etiologies for end-stage renal disease were
glomerulonephritis (32.8%) and polycystic kidney disease
(13.3%; Table 2). The mean number of human leukocyte
antigen (HLA) mismatches and percentage of panel-
reactive antibodies were similar between groups.
Immunosuppressive Drug Dosage and Trough Levels
Mean sirolimus and tacrolimus whole blood trough levels
and doses are depicted in Figs 1A and 1B. For both groups,
sirolimus levels were maintained within the targeted range
Fig 1. (A) Mean SRL, trough and dose. (B) Mean TAC trough
and dose. P value for comparison between rTAC versus sTAC
trough levels. SRL, sirolimus; TAC, tacrolimus; rTAC, reduced-
dose TAC plus SRL; sTAC, standard-dose TAC plus SRL.
Fig 2. Mean calculated creatinine clearance. rTAC, reduced-
dose tacrolimus plus sirolimus; sTAC, standard-dose tacrolimus
plus sirolimus.
Fig 3. Mean serum creatinine. rTAC, reduced-dose tacrolimus
plus sirolimus; sTAC, standard-dose tacrolimus plus sirolimus.
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adherence. As expected, sirolimus levels were signiﬁcantly
higher (P < .05) in the rTAC group than in the sTAC group
at all time points. Mean tacrolimus levels for the rTAC
group were maintained within the targeted range except at
weeks 1 and 3, when they exceeded target levels by 0.2 ng/mL
(7.2  3.7 ng/mL, target 3 to 7 ng/mL) at week 1, and by
0.1 ng/mL (7.1  3.7 ng/mL, target 3 to 7 ng/mL) at week 3.
Mean tacrolimus levels in the sTAC group were maintained
within the targeted range throughout the study. As expected,
the rTAC group exhibited signiﬁcantly lower tacrolimus
blood levels at all time points compared with the sTAC group
(P < .05).
Mean corticosteroid dose administration was consistent
with the standard protocol taper regimen. Minor variations
were observed across centers.
Primary Endpoint
In those patients remaining on therapy, mean creatinine
clearance was signiﬁcantly improved in the rTAC group by 3
months, and the differences between groups remained
statistically signiﬁcant for the duration of the study (Fig 2).
By the primary endpoint of 6 months, rTAC patients
exhibited signiﬁcantly higher mean calculated creatinine
clearance (63.8  17.3 mL/min) than did sTAC patients
(52.7  18.9 mL/min, P ¼ .005).Serum Creatinine
In patients remaining on therapy at 6 months, a trend
toward lower mean serum creatinine in the rTAC group
(136.3  45.3 mmol/L) compared with the sTAC group
(153.0  47.3 mmol/L, P ¼ .085) was observed, although the
difference did not reach statistical signiﬁcance (Fig 3).
Acute Rejection
The overall incidence of AR was 17.5% (n ¼ 11) in the
rTAC group and 7.7% (n ¼ 5) in the sTAC group
(P ¼ .095). No statistically signiﬁcant difference occurred
between groups in the time to ﬁrst BCAR. All rejections
were mild to moderate in severity and responded to corti-
costeroid therapy. Of the 11 BCARs in the rTAC group, 4
were grade IA, 5 were grade IIA, and 2 were grade IIB.
Among patients in the sTAC group with BCARs (n ¼ 5),
4 were grade IA and 1 was grade IIB. Among patients
experiencing BCARs, no difference was noted in donor
source or in the presence or grade of chronic or sclerosing
nephropathy between groups. Antibody therapy was used to
treat rejection in 7 patients in the sTAC group and in 5
patients in the rTAC group. Additionally, 2 patients in the
sTAC group and 2 patients in the rTAC group were treated
for episodes considered rejections either without biopsy or
graded as borderline by the investigator.
Table 3. Incidence of Selected Treatment-Emergent
Adverse Events
Adverse event, n (%) rTAC (n ¼ 63) sTAC (n ¼ 65)
Anemia 18 (28.6) 17 (26.2)
Hyperlipidemia 17 (27.0) 15 (23.1)
Hypercholesterolemia 8 (12.7) 9 (13.8)
Peripheral edema 10 (15.9) 11 (16.9)
Leukopenia 10 (15.9) 9 (13.8)
Thrombocytopenia 9 (14.3) 7 (10.8)
Arthralgia 9 (14.3) 4 (6.2)
Diarrhea 8 (12.7) 17 (26.2)
Vomiting 8 (12.7) 10 (15.4)
Nausea 5 (7.9) 9 (13.8)
ALT (SGPT) increased 1 (1.6) 7 (10.8)
AST (SGOT) increased 0 (0.0) 6 (9.2)a
Hyperglycemia 3 (4.8) 8 (12.3)
New-onset diabetes mellitus 9 (14.3) 8 (12.3)
Hypertension 2 (3.2) 7 (10.8)
ALT, alanine aminotransaminase; AST aspartate aminotransferase; rTAC,
reduced-dose tacrolimus; sTAC, standard-dose tacrolimus; SGPT, serum
glutamic-pyruvic transaminase; SGOT, serum glutamic oxaloacetic transaminase.
aP < .05; P ¼ not signiﬁcant, all other comparisons.
Table 4. Incidence of Treatment-Emergent Infections
Infection, n (%) rTAC (n ¼ 63) sTAC (n ¼ 65)
Candida 2 (3.2) 4 (6.2)
Sepsis 1 (1.6) 3 (4.6)
Cytomegalovirus 3 (4.8) 5 (7.7)
Pneumonia 2 (3.2) 6 (9.2)
Herpes simplex 1 (1.6) 0 (0.0)
Herpes zoster 0 (0.0) 1 (1.5)
Urinary tract infection/pyelonephritis 8 (12.7) 3 (4.6)
Lymphocele 6 (9.5) 7 (10.8)
Dehiscence 3 (4.8) 1 (1.5)
Wound infection 1 (1.6) 1 (1.5)
P ¼ not signiﬁcant, all comparisons. rTAC, reduced-dose tacrolimus; sTAC,
standard-dose tacrolimus.
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occurred in the 19 patients randomly assigned to rTAC
(31.6%) and 0 BCARs occurred in the 17 patients enrolled
in the sTAC group (P ¼ .023). All rejections occurred within
the ﬁrst 30 days after transplantation. Analysis revealed that
subtherapeutic sirolimus and tacrolimus concentrations in
the early post-transplant period may have contributed to the
development of these rejections. A subsequent protocol
amendment mandated an increase in sirolimus and tacroli-
mus dosages to ensure that targeted immunosuppressant
levels were readily achieved early after transplantation.
Target sirolimus and tacrolimus trough concentrations were
not changed. After the amendment, the incidence of AR
was similar between groups: rTAC, 11.4% (n ¼ 5/44);
sTAC, 10.4% (n ¼ 5/48, P ¼ .1).
Patient and Graft Survival
No signiﬁcant differences in patient survival were observed
between the rTAC and sTAC groups at 6 months post-
transplantation (95.2% vs 96.9%, respectively; P ¼ .623).
The causes of patient death were pulmonary hemorrhage,
hemolytic uremic syndrome, and retroperitoneal hematoma
in the rTAC group, and sepsis and cardiac arrest in the
sTAC group.
Graft survival at 6 months post-transplantation was
excellent in both the rTAC and sTAC groups (93.7% vs
98.5%, respectively; P ¼ .160). Three patients in the rTAC
group with BCARs subsequently lost their grafts. Of 5
patients in the sTAC group with BCARs, 4 maintained their
grafts and 1 had no data available.
Adverse Events and Discontinuations
No signiﬁcant differences were observed between treatment
groups in the incidence of common adverse events,
including hypertension, new-onset diabetes mellitus, or
dyslipidemia (Table 3). Similarly, no statistically signiﬁcant
differences in infection rates occurred between groups
(Table 4).
Overall, lipid parameters, including serum cholesterol
and triglycerides, were similar between treatment groups
throughout the study, except at screening, when serum
cholesterol values differed between the sTAC and rTAC
groups (5.4 vs 4.9 mmol/L, respectively, P ¼ .046). The
incidence of hypercholesteremia (13.8% vs 12.7%, respec-
tively; P ¼ 1.000) and hyperlipidemia (23.1% vs 27.0%,
respectively; P ¼ .685) were not signiﬁcantly different
between groups. The use of lipid-lowering therapy was
similar between the sTAC (13.8%) and rTAC (7.9%)
groups, as was the use of antihypertensives for blood pres-
sure. Serum chemistries and hematologic parameters,
including white blood cell and platelet counts, hemoglobin,
and hematocrit, were similar between groups except for the
period within 36 hours of hospital discharge, in which both
white blood cell (7.2 vs 6.3  109/L; P ¼ .026) and platelet
counts (261.6 vs 217.4  109/L; P ¼ .011) differed
signiﬁcantly between the sTAC and rTAC groups,respectively. No patients in the rTAC group experienced
moderate (>150 U/L) or severe (>500 U/L) elevations in
aspartate aminotransferase (AST). In the sTAC group, 1
patient (1.6%, hepatitis B seropositive) had a moderate
(>150 U/L) elevation in AST; no severe elevations in AST
were observed. Moderate elevations (>150 U/L) in alanine
transaminase (ALT) were observed in 3 patients (4.8%,
1 hepatitis B seropositive) in the rTAC group and in
5 patients (7.9%) in the sTAC group. No elevations in
AST or ALT (>150 U/L) were noted among hepatitis
C-seropositive patients. Two malignancies were reported:
1 patient in the rTAC group had a basal-cell carcinoma of
the lip, and 1 patient in the sTAC group experienced post-
transplant lymphoma.
Thirty-three (25.8%) patients withdrew from the study: 15
(23.8%) in the rTAC group and 18 (27.7%) in the sTAC
group (P ¼ .688). The primary reason for discontinuation
was an adverse event: 11 (17.5%) in the rTAC group and 14
(21.5%) in the sTAC group. Four patients withdrew from
the study because of lack of efﬁcacy: 2 in the rTAC group
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resulted in AR and graft loss, 1 at day 9 and 1 at day 34. In
the sTAC group, both cases resulted in AR and graft loss, 1
at day 3 and 1 at day 71. Speciﬁc reasons for withdrawal in
the sTAC group included infection (n ¼ 3, including 2
infectious pneumonias), tacrolimus nephrotoxicity (n ¼ 2),
gastrointestinal complaints (n ¼ 2), withdrawal of consent
(n¼ 2), graft loss due to thrombosis (n ¼ 1), hypersensitivity
to tacrolimus (n ¼ 1), tremor (n ¼ 1), polyneuropathy
(n ¼ 1), bilateral pain in heels (n ¼ 1), pneumopathy
(n ¼ 1), and post-transplant lymphoma (n ¼ 1). Similarly,
speciﬁc reasons for withdrawal in the rTAC group included
infection (n ¼ 2, including 1 pseudomonas pneumonia and 1
endocarditis), wound complications (n ¼ 2, including
dehiscence and lymphocele developing an abscess), siroli-
mus intolerance (n ¼ 2), arthralgia (n ¼ 1), voluntary
withdrawal (n ¼ 1), hypertriglyceridemia (n ¼ 1), tubu-
lointerstitial nephritis (n ¼ 1), pneumonitis (n ¼ 1), syno-
vitis (n ¼ 1), and death (n ¼ 1). Of those who withdrew
early, sTAC patients exhibited signiﬁcantly higher baseline
total cholesterol values compared with rTAC patients (5.5 
1.23 vs 4.3  0.97 mmol/L, respectively; P ¼ .024) and had
signiﬁcantly more HLA mismatches (3.2  0.99 vs 2.3 
1.05, respectively; P ¼ .025).DISCUSSION
The results from this prospective, randomized trial
demonstrate that, in the absence of antibody induction,
a regimen of rTAC and corticosteroids in low- to moderate-
risk renal allograft recipients provides adequate prophylaxis
against AR and is associated with signiﬁcantly improved
renal allograft function, based on the primary endpoint of
this study, creatinine clearance27 at 6 months. The
improvement in renal function observed in the rTAC cohort
was not unexpected. The use of CNIs at therapeutic doses
sufﬁcient to prevent allograft rejection is known to reduce
glomerular ﬁltration rates by approximately 15% to 25%
and may lead to tubulointerstitial ﬁbrosis.28-30 The
improvement in glomerular ﬁltration rate among rTAC
patients was observed despite a trend toward a higher
incidence of BCARs in this group and a trend toward lower
mean serum creatinine in the rTAC group compared with
the sTAC group, although the difference was not signiﬁcant.
Renal function within the ﬁrst year after transplantation
may be an important factor inﬂuencing graft survival.31-34
From the analysis of Hariharan et al, renal allograft recip-
ients with a serum creatinine level of 1.5 mg/dL at 1 year
and/or a change in creatinine  0.3 mg/dL between months
6 and 12 after transplantation have a substantially lower
projected graft half-life than all other groups, regardless of
prior AR.34 Although the duration of follow-up in our study
was only 6 months, the rTAC group experienced a signiﬁ-
cant improvement in Nankivell creatinine clearance.
When an early increased incidence of AR was identiﬁed
in the rTAC group, analysis revealed that this was likely due
to underachieved target levels of sirolimus and tacrolimus inthe early postoperative period, prompting a protocol
amendment to increase the initial dosage of both sirolimus
and tacrolimus to ensure rapid achievement of targeted
concentrations of both agents. Of note, the protocol-
mandated target concentrations for sirolimus and tacroli-
mus were not changed; additionally, it should be noted that
the amendment change did not result in signiﬁcantly higher
immunosuppressant trough levels, as overall mean target
levels essentially remained within range throughout the
duration of the study. Following the protocol amendment,
the adjustment of the initial dosages of sirolimus and
tacrolimus proved effective in AR prophylaxis, as indicated
by a similar incidence of BCARs between treatment groups.
These results emphasize the importance of optimal siroli-
mus and tacrolimus exposure to achieve adequate trough
levels of both drugs in the early post-transplant period.
A fundamental objective of combining the two immuno-
suppressants was to reduce dosages of both drugs with the
goal of improving patient compliance and decreasing
adverse events while maintaining effective prophylaxis
against AR. The combination of sirolimus and tacrolimus is
known to exhibit immunosuppressive synergy.15 Numerous
single-center reports describe sirolimus/tacrolimus-based
immunosuppression in organ transplant recipients.17-25
Consistent with the ﬁndings of our study, a retrospective
analysis by El-Sabrout et al19 emphasized the use of siroli-
mus loading doses to increase rejection-free survival. In
a pilot study of early tacrolimus withdrawal, Grinyo et al
reported improved renal function and blood pressure in
patients randomly assigned to a regimen of tacrolimus
withdrawal versus those who remained on standard-dose
tacrolimus and sirolimus.24 These investigators also high-
lighted the importance of achieving target sirolimus and
tacrolimus levels in the early period after transplantation.
These ﬁndings of CNI withdrawal are further supported by
the results of the Rapamune Maintenance Regimen trial
that demonstrated improved renal allograft survival, renal
function, and blood pressure after early cyclosporine with-
drawal and sirolimus maintenance therapy.35 An alternative
strategy to limit AR may include the use of antibody
induction. Early experience using antibody induction fol-
lowed by reduced tacrolimus and sirolimus dosages has
demonstrated success in minimizing the risk of rejec-
tion,36,37 but these beneﬁts must be weighed against the
potential for increased risk of infection and/or post-
transplant lymphoproliferative disease.
Contrary to the results of this study, an analysis by Meier-
Kriesche et al of 44,915 adult renal transplant recipients
from the Scientiﬁc Renal Transplant Registry concluded
that the combination of sirolimus and tacrolimus is associ-
ated with signiﬁcantly worse graft survival compared with
tacrolimus plus mycophenolate mofetil (MMF). It is
important to note that this analysis was conducted using
a retrospective database.38 The results from the present
study indicate that the combination of tacrolimus and siro-
limus was generally well tolerated. No unexpected or
unusually pronounced adverse events were identiﬁed, and
SIROLIMUS PLUS REDUCED-DOSE TAC 2139concomitant use of rTAC and sirolimus did not appear to
place patients at increased risk for speciﬁc adverse events.
Importantly, the use of sirolimus to minimize chronic
tacrolimus exposure may have the potential to reduce the
incidence and severity of tacrolimus-associated adverse
events, such as nephrotoxicity and hypertension. No statis-
tically signiﬁcant differences were observed between groups
in the incidence, type, or severity of adverse events,
including hematologic toxicity (leukopenia, thrombocyto-
penia, anemia), hypertension, dyslipidemia, infection
(including pneumonia), wound complications (including
lymphocele and dehiscence), and malignancy. While not
statistically signiﬁcant, there were increased incidences of
arthralgia and urinary infection in the rTAC groups and
diarrhea, nausea, hyperglycemia, hypertension, and
increases in AST/ALT in the sTAC groups; from a clinical
perspective, these warrant consideration, as do any known
adverse effects with sirolimus and tacrolimus. Gonwa et al
reported that the combination of sirolimus and standard-
dose tacrolimus may exacerbate nephrotoxicity and result
in inferior renal function and higher blood pressure
compared with MMF and standard-dose tacrolimus.22
Lo et al also reported a high incidence of biopsy-proven
tacrolimus nephrotoxicity with the combined use of full
doses of tacrolimus and sirolimus.17 Furthermore, tacroli-
mus generally has a less signiﬁcant impact on lipids, a known
adverse effect of sirolimus compared with cyclosporine.39,40
A limitation of this study was that it was not adequately
powered to accurately assess the risk of AR. The study
population was generally considered to be of low immuno-
logic risk, predominantly consisting of nonsensitized white,
European recipients of a primary allograft. Prospective
protocol biopsies were not performed and, therefore, we
cannot draw any conclusions about the incidence or inﬂu-
ence of subclinical rejection or if observed improvements in
renal function correlated with improved histology. The
potential beneﬁts of improved renal allograft function as
observed in the rTAC group must be weighed against the
potential risk for AR.
In conclusion, the results of this prospective randomized
trial demonstrate that, in a population of low- to moderate-
risk renal allograft recipients, a regimen of sirolimus, rTAC,
and corticosteroids achieves superior renal function while
maintaining an acceptable incidence of ARs in the ﬁrst
6 months after transplantation compared with a regimen of
sirolimus, sTAC, and corticosteroids. When using a regimen
of rTAC plus sirolimus and corticosteroids in the absence of
antibody induction, it is critical to ensure that therapeutic
levels of sirolimus and tacrolimus are achieved early in the
postoperative period to minimize the risk of early AR. The
observations from our study suggest that the balance
between efﬁcacy and toxicity obtained with this combination
may be more favorable if tacrolimus levels are further
lowered or if tacrolimus is eliminated altogether. Further
study with longer follow-up will be necessary to fully char-
acterize the safety of this immunosuppressive combination
and to determine if the beneﬁt of improved renal functionobserved in this study correlates with improved long-term
graft survival.
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